Pharmaids Pharmaceuticals Ltdte (BSE: 524572) is a Bengaluru, Karnataka-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹105 Cr, it ranks #3,201 by market cap among the 6,197 Indian listed companies on FinBizNet, and #15 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹28.50 (as of 16 Nov 2026), the share price is 47.1% below its 52-week high of ₹53.90 and 11.3% above its 52-week low of ₹25.60. The share price is down 39.4% over one year and down 16.2% over three months.
| Current Price | ₹28.50 |
|---|---|
| Market Cap | ₹105 Cr |
| BSE Code | 524572 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -17.82% |
| Return on Assets | -9.39% |
| 52-Week Range | ₹25.60 – ₹53.90 |
| 1-Year Price Change | -39.4% |
| 3-Month Price Change | -16.2% |
| Beta (1Y) | -0.15 |
| Headquarters | Bengaluru, Karnataka |
| Website | www.pharmaids.com |
| Revenue | ₹0 Cr |
|---|---|
| Net Profit | ₹2 Cr |
| EPS (Basic) | ₹0.61 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Pharmaids Pharmaceuticals Ltdte reported revenue of ₹0 Cr in Q1 FY27, down 100.0% from ₹1 Cr in Q1 FY26 and down 100.0% from ₹3 Cr in Q4 FY26. It posted a net profit of ₹2 Cr for the quarter, against a net loss of ₹4 Cr in Q1 FY26. Across the 8 quarters from Q2 FY25 to Q1 FY27, quarterly revenue ranged from ₹0 Cr (Q1 FY27) to ₹6 Cr (Q2 FY26). The company reported a net loss in 7 of these 8 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹0 Cr | ₹2 Cr | — |
| Q4 FY26 | ₹3 Cr | −₹1 Cr | −48.7% |
| Q3 FY26 | ₹1 Cr | −₹3 Cr | −374.7% |
| Q2 FY26 | ₹6 Cr | −₹2 Cr | −27.6% |
| Q1 FY26 | ₹1 Cr | −₹4 Cr | −389.3% |
| Q4 FY25 | ₹0 Cr | −₹3 Cr | −2353.8% |
| Q3 FY25 | ₹1 Cr | −₹2 Cr | −131.4% |
| Q2 FY25 | ₹1 Cr | −₹1 Cr | −121.7% |
Standalone figures (₹ crore, XBRL filings).
Delivery averaged 82.8% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Pharmaids Pharmaceuticals Limited, together with its subsidiaries, provides contract research and manufacturing services for pharma, biotech, agro, and chemical industries in India. The company offers pharma intermediates, such as Dichloro Benzoyl nitrile, hydrazine carboximidamide 2 methane, pyridine carbonitrile,pyridine carboxylic acid, 8-chloro-10, 11-dihydro-4-aza-5H-dibenzo cycloheptene-5-one, 8-chloro-6,11-dihydro-11 cyclohepta pyridine,2-amino-5-methylthiopene-3-carbonitrile, 5-methyl-2-amino]thiophene-3-carbonitrile, 4-amino-2-methyl-10h-thiene benzodiazepine hydrochloride, 2,4-diamino-6-chloropyrimidine, hydronopol, squalene, 5-chloro-3-phenylanthranil, 2-amino-2,5-dichlorobenzophenone, 6-fluoro-3-4-piperidinyl-1,2-benzisoxazole hcl, 3-2-methyl-4H-pyrido pyrimidin-4-one, 4-n-hexyl resorcinol, triazole kopoxil, CAB-60, CABER-4, CAB-70, DTV, and avobenzone. It also provides active pharmaceuticals ingredients, including voglibose, silodosin, vitamin K2-7, UDCA, P5P, fluralaner,
1. Manufacturing and Selling of Drugs Formulation-This segment produces and markets pharmaceutical formulations in India. It offers allopathic, herbal ayurvedic, and natural drug formulations in various forms, such as tablets, capsules, liquids, powders, etc.
1. Providing Contract Research and Manufacturing Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,79,494 Cr | 73.6 | 16.98% | ₹4,979 Cr | +30.4% |
| Aether Industries Limited | ₹21,710 Cr | 101.8 | 9.81% | ₹347 Cr | +127.8% |
| Alivus Life Sciences Ltd | ₹17,862 Cr | 31.5 | 18.36% | ₹682 Cr | +64.0% |
| Aarti Pharmalabs Ltd | ₹8,374 Cr | 52.5 | 8.49% | ₹610 Cr | +15.4% |
| Solara Active Pharma Sciences Limited | ₹3,225 Cr | n/m | -0.63% | ₹417 Cr | +22.1% |
| Sai Parenteral's Limited | ₹2,235 Cr | 115.8 | 2.88% | ₹195 Cr | — |
| KRM Ayurveda Limited | ₹521 Cr | 25.9 | 17.54% | ₹32 Cr | — |
| Trident Lifeline Limited | ₹511 Cr | 26 | — | — | +37.6% |
| Pharmaids Pharmaceuticals Ltdte | ₹105 Cr | n/m | -17.82% | ₹0 Cr | -39.4% |
Listed by market capitalisation. Ratios are shown for context only.
Pharmaids Pharmaceuticals Ltdte is trading at ₹28.50, with a market capitalisation of ₹105 Cr.
Pharmaids Pharmaceuticals Ltdte operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Pharmaids Pharmaceuticals Ltdte has a return on equity of -17.82%.
Pharmaids Pharmaceuticals Ltdte is listed on the BSE under the scrip code 524572.
Pharmaids Pharmaceuticals Ltdte's share price is down 39.4% over one year and down 16.2% over three months. Its 52-week range is ₹25.60 to ₹53.90.
In Q1 FY27, Pharmaids Pharmaceuticals Ltdte reported revenue of ₹0 Cr and net profit of ₹2 Cr, with basic EPS of ₹0.61 (standalone, parsed from the company's exchange filing).
Pharmaids Pharmaceuticals Ltdte reported revenue of ₹0 Cr in Q1 FY27, down 100.0% from ₹1 Cr in Q1 FY26 and down 100.0% from ₹3 Cr in Q4 FY26.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.